KR880009636A - 리포좀 조성물 및 그의 제조방법 - Google Patents

리포좀 조성물 및 그의 제조방법 Download PDF

Info

Publication number
KR880009636A
KR880009636A KR1019880001950A KR880001950A KR880009636A KR 880009636 A KR880009636 A KR 880009636A KR 1019880001950 A KR1019880001950 A KR 1019880001950A KR 880001950 A KR880001950 A KR 880001950A KR 880009636 A KR880009636 A KR 880009636A
Authority
KR
South Korea
Prior art keywords
composition
liposome
anionic surfactant
acyl group
drug
Prior art date
Application number
KR1019880001950A
Other languages
English (en)
Inventor
나오루 하마구찌
가쓰미 이가
야스아끼 오가와
Original Assignee
우메모또 요시마사
다께다 야꾸힝 고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또 요시마사, 다께다 야꾸힝 고오교 가부시끼가이샤 filed Critical 우메모또 요시마사
Publication of KR880009636A publication Critical patent/KR880009636A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음.

Description

리포좀 조성물 및 그의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도, 제2도 및 제3도는 실험예 1-2에 있어서, 쥐에서의 6-CF-포획 리포좀 조성물의 정맥내 투여후 시간과 6-CF 혈중 농도 사이의 관계를 나타낸다.

Claims (12)

  1. 그 막이, 아실기가 불포화아실기인 인지질 및 37℃이상의 크라프트 점을 갖는 음이온성 계면활성제로 구성된 것인, 리포좀내에 약제가 포획되어 있는 리포좀 조성물.
  2. 제1항에 있어서, 리포좀막의 상전이 온도가 약 37∼60℃ 범위임을 특징으로 하는 조성물.
  3. 제1항에 있어서, 음이온성 계면활성제가 다음 일반식으로 나타내지는 것임을 특징으로 하는 조성물.
    [상기 식중, R 은 설페이트기에 의해 치환될 수도 있는 12 이상의 탄소원자를 갖는 알킬기이고; X 는--또는이고; Y1는,또는이고; Y1는-또는이고; Z 는 -SO3 -M+또는 -SO4 -M+(M 은 알칼리 금속원소이다)이고; m 은 O(직접 결합) 또는 1이고: n 은 O(직접결합)∼2의 정수이며; 단 X 가 -CONH- 또는이면 Y2는 O(직접결합)이고 X 가이면 n 은 O(직접 교환)이다.]
  4. 제1항에 있어서, 음이온성 계면활성제가 아실타우린 또는 아실메틸타우린의 염임을 특징으로 하는 조성물.
  5. 제1항에 있어서, 약제가 옥탄올과 물사이에서의 그의 분배계수의 대수가 10이하인 것임을 특징으로 하는 조성물.
  6. 제1항에 있어서, 약제가 항종양제, 림포킨, 생리적으로 활성인 펩티드, 항생제, 비타민, 원생동물박멸제, 효소,혈액응고방지제, 항알레르기체, 면역 활성화제, 순환계의 약제 도는 대사활성화제임을 특징으로 하는 조성물.
  7. 제6항에 있어서, 항종양제가 백금 화합물임을 특징으로 하는 조성물.
  8. 제7항에 있어서, 배금 화합물이 시스플라틴임을 특징으로 하는 조성물.
  9. 제6항에 있어서, 항종양제가 그의 막이 약 40∼55℃의 상전이온도를 갖는 리포좀내에 포획되어 있음을 특징으로 하는 조성물.
  10. (1) 37℃이상의 크라프트 점을 갖는 음이온성 계면활성제를 그 임계 미셀 농도 이상의 온도로 함유하는 수성 매질을 제조하고, (2) 생성된 수성 매질을 그의 아실기가 포화아실기인 인지질과 혼합하여 에멀션 또는 현탁액을 제조하고, 공정(1) 및/또는 (2)에서 유효량의 약제를 첨가하고, (3) 생성된 에멀션 또는 현탁액을 리포좀 소포를 제조하는데 이용하여 리포좀 막이 상기 계면활성제 및 인지질로 구성되도록 함을 특징으로 하는 약제를 포획하는 리포좀 조성물의 제조방법.
  11. 제10항에 있어서, 리포좀 소포를 REV, MLV, SUV, 또는 SPLV 의 제조방법에 의해 제조함을 특징으로 하는 제조방법.
  12. 제10항에 있어서, 음이온성 계면활성제의 양이 인지질 100 중량부당 약 0.5∼50 중량부의 범위내에 있음을 특징으로 하는 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880001950A 1987-02-25 1988-02-24 리포좀 조성물 및 그의 제조방법 KR880009636A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP62-43442 1987-02-25
JP4344287 1987-02-25

Publications (1)

Publication Number Publication Date
KR880009636A true KR880009636A (ko) 1988-10-04

Family

ID=12663814

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880001950A KR880009636A (ko) 1987-02-25 1988-02-24 리포좀 조성물 및 그의 제조방법

Country Status (9)

Country Link
US (1) US5019394A (ko)
EP (1) EP0280492B1 (ko)
KR (1) KR880009636A (ko)
CN (1) CN88100965A (ko)
AT (1) ATE71834T1 (ko)
CA (1) CA1322171C (ko)
DE (1) DE3867866D1 (ko)
DK (1) DK86988A (ko)
HU (1) HU203278B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101309033B1 (ko) * 2012-03-16 2013-09-17 유우영 무복계면물질 및 무수무복계면물질의 제조방법

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888519A (en) * 1988-06-02 1999-03-30 The United States Of America As Represented By The Secretary Of The Army Encapsulated high-concentration lipid a compositions as immunogenic agents to produce human antibodies to prevent or treat gram-negative bacterial infections
EP0440742B1 (en) * 1988-10-27 1997-01-15 The Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
CA2033714A1 (en) * 1990-01-25 1991-07-26 Alberto Ferro Pharmaceutical preparations
DE69107844T2 (de) * 1990-04-18 1995-08-10 Takeda Chemical Industries, Ltd., Osaka Liposomenzusammensetzung.
WO1992003122A1 (de) * 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
WO1992003123A1 (en) * 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
ES2089226T3 (es) * 1990-09-06 1996-10-01 Johnson & Son Inc S C Procedimiento para estabilizar liposomas y composiciones que los contienen.
FR2677248B1 (fr) * 1991-06-04 1995-06-16 Lvmh Rech Gie Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant un extrait de brunelle.
US5593671A (en) * 1994-07-01 1997-01-14 American Cyanamid Company Method of attenuating lung capillary leak in a mammal
US6077545A (en) 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
ES2373861T3 (es) 1997-09-18 2012-02-09 Pacira Pharmaceuticals, Inc. Composiciones anestésicas liposomiales de liberación sostenida.
EP1030652B1 (en) 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
ES2325141T3 (es) 1998-07-17 2009-08-26 Pacira Pharmaceuticals, Inc. Composiciones biodegradables para la liberacion controlada de sustancias encapsuladas.
EP1140021B1 (en) 1998-12-23 2004-08-04 Idea Ag Improved formulation for topical non-invasive application in vivo
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
DE69901377T2 (de) 1999-01-27 2003-01-02 Idea Ag Nichtinvasive Impfung durch die Haut
IL158819A0 (en) * 2001-05-31 2004-05-12 Skyepharma Inc Encapsulation of nanosuspensions in liposomes and microspheres
US20040034336A1 (en) * 2002-08-08 2004-02-19 Neal Scott Charged liposomes/micelles with encapsulted medical compounds
US7517342B2 (en) * 2003-04-29 2009-04-14 Boston Scientific Scimed, Inc. Polymer coated device for electrically medicated drug delivery
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
US8128916B2 (en) * 2005-06-16 2012-03-06 L'oréal Aqueous fatty quaternary amine-containing carrier systems for water-insoluble materials
US8128917B2 (en) 2005-06-16 2012-03-06 L'oréal Aqueous polyamine-containing carrier systems for water-insoluble materials
US20060292100A1 (en) * 2005-06-16 2006-12-28 L'oreal Aqueous phospholipid-containing carrier systems for water-insoluble materials
US8128915B2 (en) * 2005-06-16 2012-03-06 L'oréal Aqueous fatty monoamine-containing carrier systems for water -insoluble materials
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
JP2009526858A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー コルチコステロイド溶液を製造する方法
EP2187869B1 (en) * 2007-08-17 2015-10-14 Celator Pharmaceuticals, Inc. Improved platinum drug formulations
FR2924430B1 (fr) * 2007-11-30 2010-03-19 Univ Bordeaux 2 Procede de preparation de nanoparticules a base de molecules ou macromolecules amphiphiles fonctionnelles et leur utilisation
JP4395537B2 (ja) * 2008-04-09 2010-01-13 株式会社資生堂 ベシクル及びそれを含む化粧料
CN104655542B (zh) * 2015-01-05 2017-06-20 北京市医疗器械检验所 一种防护产品检测用合成血液及其配制方法
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL64397A0 (en) * 1981-01-07 1982-02-28 Weder Hans G Process for the preparation of liposomal medicaments
US4670185A (en) * 1982-07-19 1987-06-02 Lion Corporation Aqueous vesicle dispersion having surface charge
EP0102324A3 (de) * 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
JPS6058915A (ja) * 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
JPS6072830A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
JPS60136508A (ja) * 1983-12-26 1985-07-20 Kao Corp ベシクル用組成物
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
PH26160A (en) * 1985-08-19 1992-03-18 Univ Texas Pharmaceutical compositions consisting of acylated phospholipids
US5041581A (en) * 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101309033B1 (ko) * 2012-03-16 2013-09-17 유우영 무복계면물질 및 무수무복계면물질의 제조방법

Also Published As

Publication number Publication date
EP0280492A2 (en) 1988-08-31
CA1322171C (en) 1993-09-14
EP0280492B1 (en) 1992-01-22
HU203278B (en) 1991-07-29
DK86988A (da) 1988-08-26
HUT52943A (en) 1990-09-28
ATE71834T1 (de) 1992-02-15
DE3867866D1 (de) 1992-03-05
US5019394A (en) 1991-05-28
EP0280492A3 (en) 1989-10-04
CN88100965A (zh) 1988-09-07
DK86988D0 (da) 1988-02-19

Similar Documents

Publication Publication Date Title
KR880009636A (ko) 리포좀 조성물 및 그의 제조방법
US4853228A (en) Method of manufacturing unilamellar lipid vesicles
EP0094692B1 (en) Coated ubidecarenone-containing liposome
US4649155A (en) Injectable solutions
DK175201B1 (da) Kompositioner omfattende antineoplastiske anthracyclinmidler indkapslet i micellulære phospholipidpartikler og fremgangsmåder til fremstilling deraf
KR890014097A (ko) 리포좀 조성물
AU7921682A (en) Preparation of liposomal medicaments
DE3775783D1 (de) Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
KR960016908A (ko) 제약학상 담체
ES2074878T3 (es) Polvo preliposomal de polieno liposomal y metodo para su preparacion.
CA1335349C (en) Liposome composition and its production
KR880001284A (ko) 단일 이중층 리포좀의 제조방법
RU2074192C1 (ru) Мурамилдипептидные производные, противогриппозная вакцина
CA2050679A1 (en) Preparation of liposome and lipid complex compositions
EP0069399B1 (en) Pharmaceutical composition containing ubidecarenone containing liposomes
DK165314C (da) Farmaceutiske praeparater i form af liposomdispersioner indeholdende acylerede phospholipider, fremgangsmaade til fremstilling deraf samt blandinger til fremstilling af liposomdispersioner
FI103178B1 (fi) Menetelmä vaikuttavaa ainetta sisältävien vesipohjaisten liposomisuspensioiden valmistamiseksi
JP2611307B2 (ja) リポソーム製剤およびその製造法
US20040137048A1 (en) Thermolabile liposome with controlled release temperature
JPH0114A (ja) リポソーム製剤およびその製造法
KR890003788A (ko) 신규한 말로네이트 유도체의 수용성 백금복합체 및 그의 제조방법
JPH0474116A (ja) リポソーム
Nishiya et al. Circular dichroism study of membrane dynamics focused on effect of monosialogangliosides
Rendi et al. Divalent cation enhancement of the agglutinability by soyabean lectin of liposomes prepared from total lipid of erythrocytes and of erythrocyte membranes
JP2972860B2 (ja) ステロール誘導体及びそれを用いたベシクル並びにそれらの製造方法

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid